Lukas Stalder

Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10

Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard et al. · Journal of Clinical Oncology · 2015 · 107 citations · Full text

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09

Oliver Gautschi, Nicholas Mach, Sacha I. Rothschild et al. · Clinical Lung Cancer · 2015 · 15 citations

Medicine, Immunology, Pathology +6

Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer

Pirus Ghadjar, Stefanie Hayoz, Vera Genitsch et al. · British Journal of Urology · 2016 · 15 citations · Full text

Prevention of Symptomatic Skeletal Events with Denosumab Administered Every 4 Weeks Versus Every 12 Weeks–A Non-Inferiority Phase III Trial: Sakk 96/12 - Reduse

Arnoud J. Templeton, Lukas Stalder, L. Albiges Sauvin et al. · Annals of Oncology · 2014 · 12 citations · Full text

Bone Disease, Rheumatology, Sakk 96/12 +5

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).

Arnoud J. Templeton, Lukas Stalder, J. Bernhard et al. · Journal of Clinical Oncology · 2014 · 11 citations

Bone Disease, Rheumatology, Sakk 96/12 +15